Yale SPORE in Lung Cancer Career Enhancement Program

节目概要 在肺癌领域工作的医生科学家的数量并没有跟上肺癌的总体增长速度。 医学研究界或随着我们基础知识的增长，导致越来越多的 未实现的基础和转化研究机会。耶鲁是唯一适合帮助重建这个基地 我们对转化研究的坚定承诺。耶鲁大学的职业提升计划（CEP） 肺癌孢子（YSILC）的目的是为正在进行的努力和新的 努力解决这个问题。CEP的目标是教育新一代 致力于肺癌转化研究的研究人员。CEP具有实质性的机构 在资金和基础设施方面的承诺。例如，我们在耶鲁大学的翻译研究办公室 (also由Herbst博士领导，YSILC PI）一直致力于提供早期种子资金和翻译 支持年轻的研究人员在他们的研究生涯的早期。潜在的CEP候选人包括有前途的 有兴趣在转化型肺癌研究中建立职业生涯的初级教师和/或 已建立的研究人员，其先前的研究已在其他领域，并希望过渡到 肺癌的重点研究。初级教师获奖者将与导师谁是更成熟的配对 肺癌研究者成功指导的记录。这样，YSILC将 刺激下一代医生科学家的发展，解决最具挑战性的问题， 肺癌的治疗方法

PROGRAM SUMMARY The number of physician-scientists working in lung cancer has not kept pace with the overall growth of the medical research community or with the growth in our basic knowledge base, resulting in an increasing number of unrealized basic and translational research opportunities. Yale is uniquely suited to helping rebuild this base with our strong commitment to translational research. The Career Enhancement Program (CEP) of the Yale SPORE in Lung Cancer (YSILC) has been designed to contribute substantively to ongoing efforts and new initiatives attempting to address this problem. The goal of the CEP is to educate a new generation of investigators committed to translational research in lung cancer. The CEP has substantial institutional commitment, both in terms of funding and infrastructure. For example, our translational research office at Yale (also led by Dr. Herbst, YSILC PI) has been committed to providing early seed funding and translational support to young investigators early in their research careers. Potential CEP candidates include promising junior faculty who are interested in establishing their careers in translational lung cancer research and/or established investigators whose previous research has been in other areas and would like to transition into lung cancer focused research. Junior faculty awardees will be paired with mentors who are more established lung cancer investigators with a documented record of successful mentoring. In this way, the YSILC will stimulate the development of the next generation of physician scientists, addressing the most challenging issues in lung cancer research.